IL230487B - 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them - Google Patents

6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them

Info

Publication number
IL230487B
IL230487B IL230487A IL23048714A IL230487B IL 230487 B IL230487 B IL 230487B IL 230487 A IL230487 A IL 230487A IL 23048714 A IL23048714 A IL 23048714A IL 230487 B IL230487 B IL 230487B
Authority
IL
Israel
Prior art keywords
oxaborol
methylbenzofuran
methylsulfonamido
dihydrobenzo
fluorophenyl
Prior art date
Application number
IL230487A
Other languages
English (en)
Hebrew (he)
Other versions
IL230487A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL230487(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL230487A0 publication Critical patent/IL230487A0/en
Publication of IL230487B publication Critical patent/IL230487B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL230487A 2011-08-19 2014-01-16 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them IL230487B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23
PCT/US2012/050268 WO2013028371A1 (en) 2011-08-19 2012-08-10 Benzofuran compounds for the treatment of hepatitis c virus infections

Publications (2)

Publication Number Publication Date
IL230487A0 IL230487A0 (en) 2014-03-31
IL230487B true IL230487B (en) 2019-06-30

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL230487A IL230487B (en) 2011-08-19 2014-01-16 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them

Country Status (38)

Country Link
US (2) US8927593B2 (OSRAM)
EP (2) EP2744332B1 (OSRAM)
JP (2) JP6367712B2 (OSRAM)
KR (1) KR101913800B1 (OSRAM)
CN (1) CN103732065B (OSRAM)
AR (1) AR087563A1 (OSRAM)
AU (1) AU2012299295B2 (OSRAM)
BR (1) BR112014002845A2 (OSRAM)
CA (1) CA2844086A1 (OSRAM)
CL (2) CL2014000393A1 (OSRAM)
CO (1) CO6862153A2 (OSRAM)
CR (1) CR20140078A (OSRAM)
CY (1) CY1118399T1 (OSRAM)
DK (1) DK2744332T3 (OSRAM)
DO (1) DOP2014000034A (OSRAM)
EA (1) EA032841B1 (OSRAM)
ES (1) ES2611731T3 (OSRAM)
HR (1) HRP20161743T1 (OSRAM)
HU (1) HUE030300T2 (OSRAM)
IL (1) IL230487B (OSRAM)
IN (1) IN2014CN00572A (OSRAM)
JO (1) JO3281B1 (OSRAM)
LT (1) LT2744332T (OSRAM)
MA (1) MA35443B1 (OSRAM)
ME (1) ME02588B (OSRAM)
MX (1) MX354676B (OSRAM)
PE (1) PE20141201A1 (OSRAM)
PH (1) PH12014500385A1 (OSRAM)
PL (1) PL2744332T3 (OSRAM)
PT (1) PT2744332T (OSRAM)
RS (1) RS55462B1 (OSRAM)
SG (1) SG10201606883QA (OSRAM)
SI (1) SI2744332T1 (OSRAM)
SM (2) SMT201700028T1 (OSRAM)
TW (1) TWI538915B (OSRAM)
UY (1) UY34274A (OSRAM)
WO (1) WO2013028371A1 (OSRAM)
ZA (1) ZA201401020B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606646RA (en) * 2011-08-17 2016-09-29 Glaxosmithkline Llc Therapeutic methods
MX354676B (es) 2011-08-19 2018-03-15 Glaxo Group Ltd Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
CA2967184A1 (en) * 2014-11-10 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Combination long acting compositions and methods for hepatitis c
JP2017533252A (ja) 2014-11-10 2017-11-09 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｃ型肝炎のための長時間作用型医薬組成物
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
WO2018026656A1 (en) * 2016-08-01 2018-02-08 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
CN110621672A (zh) * 2017-03-02 2019-12-27 组装生物科学股份有限公司 环状磺酰胺化合物及其使用方法
UY38051A (es) * 2018-01-17 2019-08-30 Glaxosmithkline Ip Dev Ltd INHIBIDORES DE LA PI4KIIIß
TWI873211B (zh) * 2019-10-25 2025-02-21 日商住友製藥股份有限公司 新穎取代縮環型化合物
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU5788800A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
EP3078667B1 (en) 2001-01-25 2018-11-21 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
CN1731993A (zh) * 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
EP1966181A2 (en) * 2005-12-01 2008-09-10 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis c virus
EP1988779B1 (en) 2006-02-16 2015-06-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
MX2009013332A (es) * 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
AU2009214194B2 (en) * 2008-02-14 2012-05-17 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2187893A4 (en) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US7737157B2 (en) 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2011103063A1 (en) 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
AR080433A1 (es) 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201221518A (en) 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
AU2011329485A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
SG10201606646RA (en) * 2011-08-17 2016-09-29 Glaxosmithkline Llc Therapeutic methods
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
MX354676B (es) 2011-08-19 2018-03-15 Glaxo Group Ltd Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).

Also Published As

Publication number Publication date
JP2014527529A (ja) 2014-10-16
MX354676B (es) 2018-03-15
US20150080343A1 (en) 2015-03-19
US8927593B2 (en) 2015-01-06
ES2611731T3 (es) 2017-05-10
UY34274A (es) 2013-04-05
HUE030300T2 (en) 2017-04-28
CA2844086A1 (en) 2013-02-28
TWI538915B (zh) 2016-06-21
KR20140054287A (ko) 2014-05-08
EA201490213A1 (ru) 2014-07-30
JP2017125010A (ja) 2017-07-20
AU2012299295B2 (en) 2016-03-31
EP2744332B1 (en) 2016-10-26
SMT201700028T1 (it) 2017-03-08
EP2744332A1 (en) 2014-06-25
SMT201700028B (it) 2017-03-08
HRP20161743T1 (hr) 2017-02-24
CY1118399T1 (el) 2017-06-28
CR20140078A (es) 2014-03-20
ZA201401020B (en) 2020-11-25
JO3281B1 (ar) 2018-09-16
CN103732065A (zh) 2014-04-16
US20130237501A1 (en) 2013-09-12
MX2014001989A (es) 2014-02-27
IL230487A0 (en) 2014-03-31
PT2744332T (pt) 2017-01-24
PL2744332T3 (pl) 2017-03-31
CN103732065B (zh) 2016-10-26
PH12014500385A1 (en) 2020-06-22
PE20141201A1 (es) 2014-10-03
BR112014002845A2 (pt) 2017-02-21
CO6862153A2 (es) 2014-02-10
CL2017000293A1 (es) 2017-10-06
EP3199531A1 (en) 2017-08-02
JP6367712B2 (ja) 2018-08-01
CL2014000393A1 (es) 2014-08-01
RS55462B1 (sr) 2017-04-28
EP2744332A4 (en) 2015-01-14
ME02588B (me) 2017-06-20
DOP2014000034A (es) 2014-06-01
SG10201606883QA (en) 2016-10-28
US9682999B2 (en) 2017-06-20
SI2744332T1 (sl) 2017-01-31
LT2744332T (lt) 2017-01-10
DK2744332T3 (en) 2017-01-16
KR101913800B1 (ko) 2018-11-01
WO2013028371A1 (en) 2013-02-28
EA032841B1 (ru) 2019-07-31
AU2012299295A1 (en) 2014-02-20
MA35443B1 (fr) 2014-09-01
AR087563A1 (es) 2014-04-03
TW201321390A (zh) 2013-06-01
IN2014CN00572A (OSRAM) 2015-04-03

Similar Documents

Publication Publication Date Title
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
IL229199A (en) N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
IL222878A (en) N - ((2-oxo-2,1-dihydropyridine-3-ram) methyl) -1h-indole-4-carboxamide and pharmaceuticals containing them
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL231495B (en) N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide compounds or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of osteoporosis
PL2808325T3 (pl) Podstawione azole, przeciwwirusowy składnik czynny, kompozycja farmaceutyczna, sposób ich wytwarzania i stosowania
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
IL223543A (en) Pharmaceutical preparation containing 1– (4– (4– (4,3-dichloro-2 – fluorophenylamino) –7 – methoxyquinazoline – 6 – Iloxy) piperidine – 1 – il) Prof. 2 – an – 1 – on or a common pharmaceutical salt His and an acidic addition
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
IL230484A (en) "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation
ZA201405756B (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
ZA201303695B (en) Pharmaceutical composition comprising citrate and bicarbonate salts,and use thereof for treating cystinuria
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
PH12013501509A1 (en) Treatment of cognitive dysfunction in schizophrenia
PT2722322T (pt) Derivado de 1,3-di-oxo-indeno, seu sal farmaceuticamente aceitável ou isómero ótico, seu método de preparação, e composição farmacêutica contendo o mesmo como ingrediente ativo, antiviral
BR112013007904A2 (pt) "composto, composição farmacêutica, medicamento, uso de um composto e proceso para preparar um composto"
MX2013008269A (es) Composicion farmaceutica que comprende derivados de piridona.
PT2476420E (pt) Composição farmacêutica com atividade antimicrobiana e de cicatrização rápida para administração externa, e processo de preparação da mesma
PT3882244T (pt) Composto, sal farmaceuticamente aceitável ou isómero ótico do mesmo, método para a sua preparação e composição farmacêutica para prevenção ou tratamento de doenças virais que contenha o mesmo como ingrediente ativo
EP2386301A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLOPIDINE OR PHARMACEUTICAL ACCEPTABLE SALTS AND BETA BLOCKERS, AND USE THEREOF
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease
BR112012028227A2 (pt) composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, agente terapêutico e/ou profilático para uma doença causada pela formação de trombo
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees